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independent of the bradycardiac effect
Rajesh G. Katare, MD,a,* Motonori Ando, PhD,a,c Yoshihiko Kakinuma, MD,a Mikihiko Arikawa, PhD,a Takemi Handa, MD,a
Fumiyasu Yamasaki, MD,b and Takayuki Sato, MDa
Background: In spite of recent advances in coronary interventional therapy, reperfusion injury is still considered
to be a major problem in patients undergoing surgical procedures, such as bypass grafting. Here we demonstrate
a novel therapeutic strategy against ischemia–reperfusion injury: vagally mediated prevention of reperfusion-
induced opening of mitochondrial permeability transition pore.
Methods: We investigated the effects of efferent vagal stimulation on myocardial reperfusion injury with ex vivo
and in vitro rat models. In the ex vivo model the hearts were perfused with intact vagal innervation, which allowed
us to study the effects of the vagal nerve on the heart without other systemic effects.
Results: Compared with sham stimulation, vagal stimulation exerted a marked anti-infarct effect irrespective of
the heart rate (34% 6% vs 85% 9% at a heart rate of 300 beats/min, 37% 4% vs 43% 5% at a heart rate
of 250 beats/min, and 39%  4% vs 88%  7% at a heart rate of 350 beats/min) after a 30-minute period of
global ischemia, activated cell-survival Akt cascade, prevented downregulation of the antiapoptotic protein
Bcl-2, and suppressed cytochrome-c release and caspase-3 activation. Furthermore, vagal stimulation–treated
hearts exhibited a significant improvement in left ventricular developed pressure (78  5 vs 45  8 mm Hg)
and a significant attenuation in an incremental change in left ventricular end-diastolic pressure during reperfusion.
These beneficial effects of vagal stimulation were abolished by a permeability transition pore opener, atractylo-
side. In the in vitro study with primary-cultured cardiomyocytes, acetylcholine prevented a reoxygenation-in-
duced collapse in mitochondrial transmembrane potential through inhibition of permeability transition pore
opening.
Conclusion: Vagal stimulation would be a potential adjuvant therapy for the rescue of ischemic myocardium
from reperfusion injury, and the protective effects are independent of its bradycardiac effects.C
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PAlthough reperfusion or restoration of blood flow to ische-
mic myocardium is necessary for salvage of cardiac cells
and function, reperfusion itself initiates a cascade of events
that results in cardiac cell death and dysfunction.1,2 There-
fore reperfusion injury is still considered a major problem
in patients with acute coronary occlusion or those undergo-
ing surgical procedures, such as coronary artery bypass
grafting (CABG) and transplantation. Mitochondria are the
cell’s powerhouse, the site where the vast majority of aden-
osine triphosphate (ATP) is synthesized; under pathologic
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role in cell death. Mitochondrial decision of cellular life or
death is closely linked to the electrochemical gradient built
across the inner mitochondrial membrane that is nearly im-
permeable to all ions, including protons. As one of the cru-
cial mechanisms for reperfusion injury, well known is the
reperfusion-related opening of a nonspecific pore in the in-
ner mitochondrial membrane: the permeability transition
pore (PTP). The prolonged opening of the PTP leads cells
to death through rapid depletion of ATP and activation of
death messengers, such as caspases.3
Our previous study4 demonstrated that efferent vagal
stimulation (VS), when administered before or even during
30-minute coronary occlusion, protects hearts against ische-
mia-induced lethal arrhythmias through prevention of the
loss of functional gap-junction channels. In another study5
we examined the effect of VS on ischemic insult during 3-
hour coronary occlusion, showing that VS significantly re-
duced infarct size through activation of phosphatidylinositol
3-kinase and Akt. With these in mind, we speculated that
a brief period of VS, before or during acute ischemia, would
be expected to suppress lethal arrhythmias at an early phase
of acute coronary occlusion and to reduce ischemic insult
during long-lasting occlusion. However, the effect of VS
on reperfusion injury still remains to be elucidated.ardiovascular Surgery c Volume 137, Number 1 223
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PAbbreviations and Acronyms
ACh ¼ acetylcholine
ATP ¼ adenosine triphosphate
CABG ¼ coronary artery bypass grafting
PTP ¼ permeability transition pore
SS ¼ sham stimulation
VS ¼ vagal stimulation
Since Murry and colleagues6 reported an endogenous
protective mechanism against reperfusion-related injury
(ie, ischemic preconditioning), numerous studies have
been performed to elucidate its cellular and molecular mech-
anisms. A series of detailed experimental studies by Downey
and colleagues7,8 has shown that several drugs, such as bra-
dykinin and acetylcholine (ACh), mimic ischemic precondi-
tioning through a complex pathway, including activation of
phosphatidylinositol 3-kinase and Akt, suggesting that these
drugs are potent preconditioning agents. Although ischemic
or pharmacologic preconditioning therapy has been avail-
able for more than a decade to patients undergoing CABG,
its application for patients presenting with acute myocardial
infarction is quite difficult. The primary reason is that, by
definition, the preconditioning intervention must be admin-
istered before the onset of acute myocardial infarction. The
cardioprotective intervention that can be performed during
coronary occlusion has therefore been expected for years,
as has postconditioning therapy at reperfusion.9,10 Based
on these clinical backgrounds and recent findings that effer-
ent VS, when administered even during acute coronary oc-
clusion, increases ACh concentration in ventricular
interstitial fluid11 and that Akt contributes toward inhibiting
the reperfusion-related opening of the PTP,10,12 we hypoth-
esized that VS during coronary occlusion could exert a cardi-
oprotective effect at reperfusion by targeting the PTP. In the
present study we tested this hypothesis with ex vivo and cel-
lular models of acute myocardial ischemia and reperfusion
and thus propose a new therapeutic paradigm, neurally me-
diated conditioning during coronary occlusion, as well as
preconditioning before occlusion and postconditioning at re-
perfusion.
MATERIALS AND METHODS
Male Wistar rats (SLC, Shizuoka, Japan) aged between 8 and 10 weeks
and weighing 250 20 g and 2-day-old neonatal rats were used. All animals
received humane care in compliance with the ‘‘Guide for the care and use of
laboratory animals’’ prepared by the Institute of Laboratory Animal Re-
sources and published by the National Institutes of Health (NIH publication
no. 86–23, revised 1986).
Myocardial Ischemia–Reperfusion Models
We examined the effects of efferent VS on ischemia–reperfusion injury
with ex vivo and cellular models of acute myocardial ischemia–reperfusion.
The main aim of the ex vivo study was to clarify the effects of VS on iso-224 The Journal of Thoracic and Cardiovascular Suvolumetric left ventricular function and subcellular signaling pathways of
reperfused hearts in the absence of extracardiac regulatory systems, such
as baroreflex or the sympathoadrenal system, and thus such a simplified
preparation could exclude any effects of these extracardiac regulatory mech-
anisms on cardiac and subcellular functions during reperfusion. Moreover,
to mimic the ischemia–reperfusion heart injury at the cellular level and to
clarify the direct action of efferent VS, we investigated the effect of ACh,
a neurotransmitter that is released at cardiac nerve endings by VS, on hyp-
oxia–reoxygenation cell injury.
Ex Vivo Model With Vagal Innervation
To study the effect of VS on the recovery of cardiac function during re-
perfusion, we used a global ischemia–reperfusion model with an intact va-
gal innervation. After the ascending aorta was cannulated, the heart of the
adult rat was in situ perfused in a Langendorff apparatus with filtered
Krebs–Henseleit buffer equilibrated with 5% carbon dioxide and 95% ox-
ygen. To preserve vagal innervation of the heart, we cut bilateral vagal
nerves at the cervical level and then excised the heart en bloc with the tra-
chea and esophagus, as described previously.13 A fluid-filled latex balloon
was passed into the left ventricle through the mitral valve and connected to
the pressure transducer for continuous monitoring of left ventricular pres-
sure. The balloon was inflated to set an end-diastolic pressure of 10 mm
Hg. Coronary perfusion pressure was controlled at 80 mm Hg, and coronary
flow was measured continuously.
To study the effects of VS on reperfusion injury, the right vagal nerve
was isolated, and the proximal portion was cut to exclude the effects of vagal
afferent. The efferent portion was then placed on a pair of platinum wires
and stimulated with an isolated constant voltage stimulator (SS-202J and
SEN-7203; Nihon Kohden, Tokyo, Japan) with continuous electrical rectan-
gular pulses of 0.1 ms in duration at 10 Hz. The electrical voltage of pulses
was optimized in each rat so as to obtain a 10% reduction in heart rate before
ischemia. We confirmed that a bradycardiac response of the Langendorff-
perfused heart to VS was stably reproducible for 90 minutes after the begin-
ning of perfusion (unpublished observation). Hearts were paced at 3 differ-
ent rates (250, 300, and 350 beats/min) throughout the experiment to
demonstrate the heart rate–independent effects of VS in protecting the ische-
mic myocardium.
The heart was subjected to 30 minutes of global ischemia by stopping the
perfusion of Krebs–Henseleit buffer, followed by 120 minutes of reperfusion.
Sham stimulation (SS) or VS was administered starting 5 minutes before is-
chemia and continuing for 30 minutes of reperfusion. Left ventricular pressure
and coronary flowwere digitally recorded with a laboratory computer and later
analyzed with Igor-Pro version 3.1 (WaveMetrics, Lake Oswego, Ore). To ex-
amine the effect of PTP opening on the hearts treated with SS and VS, we
added atractyloside14 (0.02 mmol/L; Sigma, St Louis, Mo) to perfusate before
ischemia. Ten animals were studied in each group of experiments.
In Vitro Cellular Model and ACh Treatment
Neonatal cardiomyocytes were isolated as described previously.4 After 4
days of culture, the cells were subjected to chemically induced hypoxia for
60 minutes with cobalt chloride (0.1 mmol/L) and then reoxygenated for
180 minutes. The effects of ACh (0.5 mmol/L), atropine (0.1 mmol/L),
and atractyloside (0.02 mmol/L) were evaluated.
Infarct Size Assessment and MTTAssay of Cell
Viability
In both in vivo and ex vivo studies, the infarcted area was determined by
using a triphenyltetrazolium chloride staining method, as described previ-
ously.4
To evaluate the effect of ACh on the viability of hypoxia–reoxygenated
cardiomyocytes, we used a colorimetric method with an MTT Cell Count
Kit (Nacalai Tesque, Kyoto, Japan), according to the manufacturer’s in-
structions.rgery c January 2009
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PATP Assay
The left ventricular samples obtained at the ends of the global ischemia
and reperfusion periods were frozen immediately in liquid nitrogen and
stored at70C until further analysis, as described previously.14 ATP assay
was performed with an ATP Bioluminescence Kit (Promega, Madison,
Wis).
Mitochondrial Swelling Assay
To examine the effect of VS on calcium-induced PTP opening, we iso-
lated mitochondria from the left ventricular tissues at ex vivo reperfusion
and measured the swelling with a spectrophotometer, as described previ-
ously.15
DePsipher Assay of Mitochondrial Transmembrane
Potential
To examine the effect of ACh on the mitochondrial transmembrane po-
tential of hypoxia–reoxygenated cardiomyocytes, we used a DePsipher Mi-
tochondrial Potential Assay Kit (Trevigen, Gaithersburg, Md), as described
previously.5
Protein Preparation and Immunoblotting
As described previously,4,5,14 the left ventricular samples obtained at the
end of the reperfusion period in the ex vivo study were prepared for immu-
noblot analysis. Equal amounts of proteins (50 mg of total protein) were
separated by means of sodium dodecylsulfate–polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene difluoride membrane (Milli-
pore, Temecula, Calif). After blocking nonspecific sites with 5% nonfat
milk in Tris-buffered saline supplemented with 0.1% Tween 20 overnight,
the membranes were probed with primary antibodies against Akt (diluted
1:1000; Cell Signaling, Danvers, Mass), phospho-Akt (diluted 1:1000,
Cell Signaling), Bcl-2 (diluted 1:1000; Santa Cruz Biotechnology, Santa
Cruz, Calif), and phospho-Bad (diluted 1:1000; Oncogene, Cambridge,
Mass). Anti-mouse and anti-rabbit immunoglobulin Gs conjugated with
horseradish peroxidase (diluted 1:2000, Santa Cruz) were used as secondary
antibodies and developed with an ECL chemiluminescence reagent (Amer-
sham, Piscataway, NJ). As described previously,14 cytochrome C was de-
tected by using the antibody against cytochrome C (diluted 1:1000, Santa
Cruz Biotechnology) from the cytosolic and mitochondrial fractions.
Caspase-3 Activity Assay for Detection of Apoptosis
To assess the effect of VS on reperfusion-induced apoptosis, we mea-
sured caspase-3 activity with a Caspase-3/CPP32 Colorimetric Assay Kit
(BioVision, Mountain View, Calif).5 The left ventricular samples from
the ex vivo study were lysed, and caspase-3 substrate was added to the cy-
tosolic extract. Caspase activity was measured with a spectrophotometer
(Ultrospec 3000; Pharmacia, Uppsala, Sweden).
Statistical Analysis
Nonparametric multiple-comparison tests among 3 or more groups were
performed by using a Steel–Dwass test16,17 with Excel Statistics version 5.0
(Esumi). Values are expressed as the mean  standard deviation.
RESULTS
Effect of VS and ACh on Reperfusion and
Reoxygenation Injury
VS reduced myocardial infarct size independent of its
bradycardiac effects. As shown in Figure 1, the control
group with a heart rate of 250 beats/min showed a small
myocardial infarct size of 43%  5%. However, other con-
trol groups with heart rates of 300 and 350 beats/min hadThe Journal of Thoracic and Clarge infarct sizes of 85%  9% and 88%  7%, respec-
tively. In contrast, VS treatment reduced the myocardial in-
farct size irrespective of the heart rate (37%  4% for 250
beats/min, 34%  6% for 300 beats/min, and 39%  4%
for 350 beats/min), thus confirming that the myocardial pro-
tection provided by VS is independent of its bradycardiac ef-
fects. Therefore for the rest of the studies, we paced the heart
at 300 beats/min with vagal nerve stimulation.
At a heart rate of 300 beats/min, the protective effects of
VS on reducing the myocardial infarct size was abolished by
treating the hearts with the PTP opener atractyloside before
reperfusion, showing large myocardial infarction (75% 
9%). The PTP opener did not have any significant effect
on the infarct size of the SS-treated hearts (Figure 1, C).
In vitro model. Although a hypoxia–reoxygenation chal-
lenge remarkably reduced the viable cell count (Figure 1,
D), ACh significantly improved cell survival (23%  2%
vs 65%  3%). A treatment with atractyloside alone had
no effect on cell viability; however, improvement of cell sur-
vival by ACh was significantly attenuated in the presence of
atractyloside (34%  2%, P< .05 vs ACh-treated cells).
Effect of VS on Functional Recovery of Reperfused
Hearts After Global Ischemia
In addition to the anti-infarct effect, VS exerted a beneficial
effect on functional recovery of reperfused hearts after global
ischemia (Table 1). When compared with the SS-treated left
ventricle, the VS-treated left ventricle showed significantly
high performance throughout the 120-minute reperfusion pe-
riod. At the end of the reperfusion period, the developed pres-
sure of the VS-treated left ventricle reached almost twice that
of the SS-treated left ventricle (78 5 vs 45 8 mm Hg, P<
.001). Such a beneficial effect of VS on functional recovery
of the reperfused left ventricle from global ischemia was sig-
nificantly attenuated by atractyloside administration into per-
fusate (54  5 mm Hg at the end of the reperfusion period,
P< .05 vs the VS-treated left ventricle). Treatment with
atractyloside alone did not significantly affect the developed
pressure of the SS-treated left ventricle.
VS also significantly prevented a progressive increase in
left ventricular end-diastolic pressure. At the end of the re-
perfusion period, the end-diastolic pressure of the SS-treated
left ventricle became 3 times as high as that of the VS-treated
left ventricle (38  4 vs 12  2 mm Hg). The decreasing
effect of VS on left ventricular end-diastolic pressure was
almost abolished by atractyloside administration.
There was no significant difference in coronary flow
among the 4 groups before ischemia (16  2 mL/min
[SS], 17  3 mL/min [VS], 16  4 mL/min [SS with atrac-
tyloside], and 17  1 mL/min [VS with atractyloside]) or
during reperfusion (12  3 mL/min [SS], 13  2 mL/min
[VS], 11  5 mL/min [SS with atractyloside], and 12  4
mL/min [VS with atractyloside]).ardiovascular Surgery c Volume 137, Number 1 225
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PFIGURE 1. Effects of vagal stimulation on reperfused hearts after global ischemia and of acetylcholine on reoxygenated cardiomyocytes after chemical
hypoxia. A, Representative left ventricular sections stained with triphenyltetrazolium chloride, with hearts paced at 300 beats/min (n ¼ 10 in each group).
HR, Heart rate; SS, sham stimulation; MI, myocardial ischemia; VS, vagal stimulation. B, Quantitative analysis showing the percentage of infarct area in
the hearts paced at different heart rates. LV, Left ventricular; SS, sham stimulation; MI, myocardial ischemia; VS, vagal stimulation. Values are expressed
as the mean  standard deviation. *P< .05 from the sham stimulation–treated group with a heart rate of 300 beats/min; #P< .05 from the sham stimula-
tion–treated group with a heart rate of 350 beats/min (n¼ 10 in each group). C, Graph showing an infarct size of the left ventricle treated with sham stimulation
(SS), vagal stimulation (VS), sham stimulation and atractyloside (SS-AT), and vagal stimulation and atractyloside (VS-AT). Each value in parentheses indicates
the number of left ventricles (n ¼ 10 in each group). D, Graph showing a percentage of viable cells in untreated, acetylcholine-treated (ACh), atractyloside-
treated (AT), ACh- and AT-treated (ACh-AT), atropine-treated (ATR), and ACh and atropine–treated (ACh-ATR) groups. For each treatment group, 5 culture
dishes were analyzed. Values are expressed as the mean standard deviation. *P<.05 from the sham stimulation–treated or untreated group; #P<.05 from
the vagal stimulation– or acetylcholine-treated groups.Effect of VS on Myocardial ATP Content at Global
Ischemia–Reperfusion
The VS-induced improvement of functional recovery of
reperfused hearts seems to be involved in myocardial bioen-226 The Journal of Thoracic and Cardiovascular Surergetics (Table 2). Global ischemia markedly reduced the
myocardial ATP content. When compared with the SS-
treated left ventricle, the VS-treated left ventricle had a sig-
nificantly high ATP content at the end of ischemia (0.50 TABLE 1. Left ventricular function during reperfusion period after 30 minutes of global ischemia
Group
Developed pressure (mm Hg)
Time after reperfusion (min)
End-diastolic pressure (mm Hg)
Time after reperfusion (min)
n 5 60 120 5 60 120
SS 10 9  2 40  4 45  8 21  3 35  4 38  4
VS 12 10  1 74  6* 78  5* 9  2* 15  3* 12  2*
SS-AT 7 9  1 43  10 44  6 21  4 28  4 37  3
VS-AT 10 10  2 46  3y 54  5y 19  3y 30  3y 35  4y
Values are presented as the mean  standard deviation. SS, Hearts treated with sham stimulation; VS, hearts treated with vagal stimulation; SS-AT, hearts treated with sham stim-
ulation and atractyloside; VS-AT, hearts treated with vagal stimulation and atractyloside. *P< .05 from the sham stimulation group; yP< .05 from the vagal stimulation group.gery c January 2009
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P0.07 vs 0.22 0.01 mmol/L per gram of wet weight) and ex-
hibited a rapid restoration of ATP content during 120-min-
ute reperfusion (1.02  0.09 vs 0.53  0.01 mmol/L per
gram of wet weight). The VS-mediated effect on myocardial
ATP content during ischemia–reperfusion was abolished by
atractyloside. The administration of atractyloside alone had
no significant effect on the myocardial ATP content.
Effect of ACh on Collapse in Mitochondrial
Transmembrane Potential of Reoxygenated
Cardiomyocytes
A mechanism for VS-induced improvement in the recovery
of myocardial ATP content during reperfusion is demonstrated
in Figure 2. When DePsipher-loaded cardiomyocytes were
subjected to reoxygenation after hypoxia, the dye remained
mostly in the cytoplasm and fluoresced green. In contrast,
the dye in ACh-treated cardiomyocytes appeared to accumu-
late within mitochondria and fluoresced bright red. However,
this ACh effect was blocked by atractyloside, whereas atracty-
loside alone had no effect. These results indicate that ACh pre-
vented the mitochondrial potential collapse that resulted in
myocardial ATP depletion. Treating the cells with atropine
also inhibited the protective effects of ACh, confirming that
ACh acts through muscarinic receptors in cardiomyocytes.
Effect of VS on Mitochondrial Swelling of
Reperfused Hearts After Global Ischemia
A reperfusion-related mitochondrial injury through the PTP
opening was accompanied by its structural change (ie, swell-
ing). As shown in Figure 3, A, the hearts treated with VS dur-
ing ischemia were insusceptible to such a mitochondrial
injury. In mitochondria isolated from the SS-treated hearts,
Ca2þ evoked a large decrease in spectrophotometric absor-
bance at 520 nm, indicating mitochondrial swelling through
the PTP opening (Figure 3, A). In contrast, mitochondria
from the VS-treated hearts showed a significant resistance to
Ca2þ-induced swelling. Atractyloside attenuated the mito-
chondrial resistance of the VS-treated hearts to Ca2þ-induced
swelling; administration of atractyloside to the SS-treated
TABLE 2. Myocardial ATP content before ischemia and at the end of
ischemia and reperfusion
ATP content (mmol/L per gram wet weight)
Group Before ischemia Ischemia Reperfusion
SS 1.68  0.04 0.22  0.01 0.53  0.01
VS 1.62  0.03 0.50  0.07* 1.02  0.09*
SS-AT 1.61  0.02 0.18  0.01 0.54  0.05
VS-AT 1.64  0.03 0.47  0.06y 0.58  0.03y
Values are presented as the mean  standard deviation (n ¼ 5 for each group). ATP,
Adenosine triphosphate; SS, hearts treated with sham stimulation; VS, hearts treated
with vagal stimulation; SS-AT, hearts treated with sham stimulation and atractyloside;
VS-AT, hearts treated with vagal stimulation and atractyloside. *P<.05 from the sham
stimulation group; yP< .05 from the vagal stimulation group.The Journal of Thoracic and Chearts had no significant effect on Ca2þ-induced mitochondrial
swelling. These results are summarized in Figure 3, B.
Effect of VS on Apoptosis-related Proteins
VS-induced activation of antiapoptotic factors inhibiting
the PTP at the reperfusion period, including Akt, Bad, and
Bcl-2, is demonstrated in Figure 4. Even though the total
amount of Akt remained unchanged, VS significantly upre-
gulated a phosphorylated form of Akt when compared with
that seen in the SS-treated hearts (389%  22% vs 75% 
10%). VS also upregulated the phosphorylated Bad (159%
 10% vs 23% 4%), thereby preventing its translocation
into the mitochondria and inhibiting its binding to Bcl-2.
Upregulation of these antiapoptotic factors by VS was sig-
nificantly attenuated by atractyloside.
In the VS-treated hearts, as a consequence of upregulation
of PTP-stabilizing proteins, such as Bcl-2, a release of
FIGURE 2. DePsipher assay in primary cultured rat cardiomyocytes. A,
Representative confocal images of normal healthy cells and untreated
(None), acetylcholine-treated (ACh), and acetylcholine- and atractyloside–
treated (ACh-AT) cells at reoxygenation after hypoxia. B, Graph showing
a percentage of cells with fluorescent red spots. For each treatment group,
5 culture dishes were analyzed. Values are expressed as the mean  stan-
dard deviation. *P< .05 from the untreated group; #P< .05 from the ace-
tylcholine-treated group.ardiovascular Surgery c Volume 137, Number 1 227
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Pmitochondrial cytochrome c to the cytosol and an activation
of caspase-3 during reperfusion were inhibited (Figure 5).
However, atractyloside significantly attenuated these benefi-
cial effects of VS on reperfused hearts.
DISCUSSION
The concept of reperfusion injury, although first reported
in animal studies, is now recognized as a clinical problem
FIGURE 3. Mitochondrial swelling assay. The isolated mitochondria were
incubated in medium containing 300 mmol/L sucrose and 10 mmol/L 3-
morpholinopropanesulfonic acid (pH 7.4) with Tris. After 1 minute, 1
mmol/L Ca2þwas added, and a decrease in absorbance caused by mitochon-
drial swelling was followed at 520 nm, indicating mitochondrial permeabil-
ity transition. A, Representative tracings of changes in spectrophotometric
absorbance at 520 nm during a calcium challenge. B, Graph showing rela-
tive changes in the absorbance from baseline at 180 seconds after the cal-
cium challenge. SS, Mitochondria isolated from sham-stimulated hearts;
VS, mitochondria isolated from vagal-stimulated hearts; SS-AT, mitochon-
dria isolated from hearts treated with sham stimulation and atractyloside;
VS-AT, mitochondria isolated from hearts treated with vagal stimulation
and atractyloside. Values are expressed as the mean  standard deviation
(n ¼ 5 for each group). *P< .05 from the sham stimulation group; #P<
.05 from the vagal stimulation group.228 The Journal of Thoracic and Cardiovascular SurFIGURE 4. Effects of vagal stimulation on Akt phosphorylation (A), Bad
phosphorylation (B), and Bcl-2 (C) of reperfused hearts. Each panel shows
quantitative densitometric results of immunoblot analysis of left ventricles
from sham-operated nonischemic hearts (SO), ischemic hearts treated
with sham stimulation (SS), ischemic hearts treated with vagal stimulation
(VS), ischemic hearts treated with SS and atractyloside (SS-AT), and ische-
mic hearts treated with vagal stimulation and atractyloside (VS-AT). Values
are normalized by reference levels obtained from the sham-operated group
and expressed as the mean standard deviation (n¼ 5 for each group). a.u.,
Arbitrary units. *P< .05 from the sham stimulation group; #P< .05 from
the vagal stimulation group.gery c January 2009
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non, and myocardial stunning and hibernation.7 The final
consequence of this event is cardiac pumping dysfunction,
leading to increased morbidity and mortality. In this study
we have demonstrated a novel therapeutic strategy against
acute ischemia–reperfusion injury using ex vivo and in vitro
experimental models. The cardioprotective effects of VS
during ischemia are evidenced as a reduction in infarct
size, rapid restoration of myocardial ATP content, improve-
ment of left ventricular dysfunction, activation of cell-sur-
vival signals, and inhibition of proapoptotic cascades, and
all these effects were independent of its bradycardiac effects.
VS During Ischemia Conditions the Myocardium
Against Reperfusion Injury
It is well known that the myocardium can be conditioned
to acquire resistance to ischemia–reperfusion injury. Pre-
FIGURE 5. Effects of vagal stimulation on a percentage of cytosolic frac-
tions of cytochrome c (A) and caspase-3 (B) activity of reperfused hearts.
n.d., Not detectable; a.u., arbitrary units; SO, sham-operated nonischemic
hearts; SS, ischemic hearts treated with sham stimulation; VS, ischemic
hearts treated with vagal stimulation; SS-AT, ischemic hearts treated with
sham stimulation and atractyloside; VS-AT, ischemic hearts treated with va-
gal stimulation and atractyloside. Values are expressed as the mean  stan-
dard deviation (n ¼ 5 for each group). *P< .05 from the sham stimulation
group; #P< .05 from the vagal stimulation group.The Journal of Thoracic and Cconditioning before prolonged ischemia and postcondition-
ing at reperfusion are inducible by brief episodes of
intermittent ischemia and pharmacologic agents.7,18 Myo-
cardial preconditioning is an option for adjuvant therapy
against reperfusion injury at CABG and transplantation
operations but not at coronary intervention for acute myo-
cardial infarction.19 In the clinical setting of acute myocar-
dial infarction, the onset of coronary occlusion is
unpredictable; however, the start of reperfusion is predict-
able and controllable.20,21 Therefore myocardial postcondi-
tioning at reperfusion is an attractive strategy against
ischemia–reperfusion injury. Zhao and associates9 first in-
troduced the phenomenon of myocardial postconditioning.
Although ischemic postconditioning has a dramatic effect
on basic cardiology, a clinical application of ischemic post-
conditioning (ie, reintroduction of ischemia at the time of re-
perfusion) might be difficult.7 Recently, a more practical
solution in clinical situations, pharmacologic postcondition-
ing, has attracted much attention.22 However, there is now
little information on its effectiveness in the clinical settings
of acute myocardial infarction.
In addition to preconditioning and postconditioning, there
might be a time window of therapeutic opportunity. Our pre-
vious study4 showed that VS protected hearts against ische-
mia-induced lethal arrhythmias by preserving gap-junction
proteins, suggesting that the conditioning of the ischemic
myocardium through manipulation of cellular and molecular
functions is inducible by VS during coronary occlusion. We
also demonstrated that ACh mimicked the beneficial effects
of VS with an in vitro cellular model5 and speculated that VS
increased an ACh release from its nerve endings, even at the
ischemic area. Recently, using a microdialysis technique,
Kawada and coworkers11 confirmed that VS increased the
myocardial interstitial ACh level in the ischemic region ap-
proximately 20 times higher than the baseline level. These
findings support that the potent cardioprotectant ACh re-
leased by VS can exert its beneficial effects on the ischemic
myocardium.
VS-induced Protection Independent of the
Bradycardiac Effect
Activation of vagal tone is known to induce bradycardia,
and therefore it is possible that VS induces its protective ef-
fects through its bradycardiac effect. In our study bradycar-
dia with a heart rate of 250 bats/min induced a significant
reduction in the myocardial infarct size with or without
VS treatment, whereas other groups with heart rates of 300
and 350 beats/min showed a large infarct size. Even though
the exact mechanism behind the bradycardia-induced pro-
tection is not known, bradycardia has been suggested to im-
prove the relationship between myocardial oxygen supply
and demand, thus favorably redistributing the ischemic
blood flow.23 In contrast, VS treatment exhibited a signifi-
cant reduction in the myocardial infarct size irrespective ofardiovascular Surgery c Volume 137, Number 1 229
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Pthe heart rate, thus confirming that the protective effects in-
duced by VS were independent of its bradycardiac effect.
VS Suppresses Reperfusion-induced Opening of the
PTP
The beneficial effects of VS would be exerted through
preservation of mitochondrial function and were blocked
by the PTP opener atractyloside. The mitochondrial pathway
of cell death has been widely demonstrated to be mediated
by the opening of the PTP. Halestrap and colleagues24 dem-
onstrated that pharmacologic inhibition of PTP opening
mimicked the effects of ischemic preconditioning and post-
conditioning. With a human trabecula model, Shanmugana-
than and associates3 also showed that PTP inhibitors
improved contractile dysfunction at hypoxia–reoxygenation
injury, supporting our results.
VS Attenuates Reperfusion–related Apoptosis
Green and Kroemer12 suggested a 3-step model for apo-
ptotic cell death: a premitochondrial phase with activation
of signal transduction cascades, a mitochondrial phase
with permeabilization of the PTP, and a postmitochondrial
phase with activation of apoptotic cascades by the proteins
released from mitochondria to the cytosol. In the present
study VS induced the phosphorylation of Akt and Bad,
which are important factors on the premitochondrial cell-
survival cascades. The phosphorylation of Bad prevented
its translocation to the mitochondria, thereby inhibiting its
binding with Bcl-2, which is essential for maintaining the
PTP in a closed state.25 VS also inhibited the release of mi-
tochondrial cytochrome c into the cytosol and the activation
of caspase-3. These results therefore provide evidence for
the ability of VS to inhibit the 3 phases of apoptotic cell
death.
LIMITATIONS
Our model of ex vivo heart perfusion with vagal nerve
stimulation is not optimized to evaluate the recovery of the
heart after cardioplegic arrest. Therefore in this study we
used global ischemia to demonstrate the effects of vagal
nerve stimulation to protect against reperfusion-induced in-
jury. However, the future studies will be focused on simulat-
ing the exact clinical condition of cardioplegic arrest of the
heart by using this model.
To adjust the intensity of stimulation at a given level in
each heart by monitoring heart rate, we selected the right va-
gus for electrical stimulation. Therefore it is not clarified
whether the electrical stimulation of the left vagal nerve
can exert the same effectiveness as that of the right vagal
nerve.
CONCLUSIONS AND CLINICAL PERSPECTIVES
Some elegant studies by Vinten-Johansen and col-
leagues26,27 have already demonstrated the protective effects230 The Journal of Thoracic and Cardiovascular Suof intermittent vagal nerve stimulation during off-pump
CABG. In our study we have used much milder stimulation
compared with that used in the previous study, and in addi-
tion to demonstrating the improvement in cardiac dysfunc-
tion, we also evaluated the molecular mechanism behind
this protection. Therefore VS could be a potential candidate
in preventing reperfusion injury in patients undergoing car-
diac surgery.
Moreover, in medical conditions a thrombolytic therapy
for acute myocardial infarction reduces mortality by as
much as 30% when treatment is begun within 6 hours of
symptom onset.28,29 Despite this impressive benefit, there
is considerable experimental evidence suggesting that suc-
cessful thrombolysis can be accompanied by reperfusion in-
jury, an inflammatory event occurring within the reperfused
myocardium that might cause additional injury and necrosis.
With the results of our present study, a catheter-based intra-
vascular VS therapy30 during coronary occlusion would be
a clinically applicable method for delivering the potent en-
dogenous cardioprotectant ACh to the ischemic myocar-
dium before reperfusion.
We thank Ms Masayo Yamamoto for her kind technical assis-
tance in immunoblotting and cell culture.
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